A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: A first-in human, single dose, controlled study

BMC Clinical Pharmacology

Volumn 9, Issue , 2009, Pages

  Varki, Roslyn ^a   Pequignot, Ed ^a   Leavitt, Mark C ^b   Ferber, Andres ^c   Kraft, Walter K ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Synageva Biopharma   (United States)

^c Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVI 014; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BIOEQUIVALENCE; BONE PAIN; CD34 SELECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; LEUKOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NEUTROPHIL COUNT; NORMAL HUMAN; THORAX PAIN; ANTIBODY PRODUCTION; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; IMMUNOLOGY; MIDDLE AGED; NEUTROPHIL; PHARMACOKINETICS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIBODY FORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FILGRASTIM; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; THERAPEUTIC EQUIVALENCY;

EID: 60749104189     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-9-2     Document Type: Article

References (13)

1. Kaushansky K Lineage-specific hematopoietic growth factors N Engl J Med 2006, 354:2034-2045. 10.1056/NEJMra052706 16687716
2. Price TH Chatta GS Dale DC Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans Blood 1996, 88:335-340. 8704192
3. Welte K Gabrilove J Bronchud MH Platzer E Morstyn G Filgrastim (r-metHuG-CSF): The first 10 years Blood 1996, 88:1907-1929. 8822908
4. Kopf B De Giorgi U Vertogen B Monti G Molinari A Turci D Dazzi C Leoni M Tienghi A Cariello A Argnani M Frassineti L Scarpi E Rosti G Marangolo M A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization Bone Marrow Transplant 2006, 38:407-412. 10.1038/ sj.bmt.1705465 16951690
5. Smith TJ Khatcheressian J Lyman GH Ozer H Armitage JO Balducci L Bennett CL Cantor SB Crawford J Cross SJ Demetri G Desch CE Pizzo PA Schiffer CA Schwartzberg L Somerfield MR Somlo G Wade JC Wade JL Winn RJ Wozniak AJ Wolff AC 2006 Update of Recommendations for the use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline J Clin Oncol 2006, 24:3187-3205. 10.1200/JCO.2006.06.4451 16682719
6. Laricchia-Robbio L Moscato S Genua A Liberati AM Revoltella RP Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum J Cell Physiol 1997, 173:219-226. 10.1002/ (SICI)1097-4652(199711)173:2<219::AID-JCP25>3.0.CO;2-9 9365526
7. Anonymous Neupogen Product Insert 2007. http://www.neupogen.com/pi.html
8. Borleffs JC Bosschaert M Vrehen HM Schneider MM van Strijp J Small MK Borkett KM Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects Clin Ther 1998, 20:722-36. 10.1016/ S0149-2918(98)80135-5 9737832
9. Wang B Ludden TM Cheung EN Schwab GG Roskos LK Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers J Pharmacokinet Pharmacodyn 2001, 28:321-42. 10.1023/ A:1011534529622 11677930
10. Auwera van Der P Platzer E Xu ZX Schulz R Feugeas O Capdeville R Edwards DJ Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim Am J Hematol 2001, 66(4):245-51. 10.1002/ajh.1052 11279634
11. Patel TB Pequignot E Parker SH Leavitt MC Greenberg HE Kraft WK Transgenic avian-derived recombinant human interferon-alpha2b (AVI-005) in healthy subjects: An open-label, single-dose, controlled study Int J Clin Pharmacol Ther 2007, 45:161-168. 17416111
12. Gabrilove JL Jakubowski A Fain K Grous J Scher H Sternberg C Yagoda Clarkson B Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium J Clin Invest 1988, 82:1454-146. 442704 2459163 10.1172/JCI113751
13. Bönig H Silbermann S Weller S Kirschke R Körholz D Janssen G Göbel U Nürnberger W Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF) - results of a prospective randomised monocentre study Bone Marrow Transplant 2001, 28:259-64. 10.1038/sj.bmt.1703136 11535993